Androgen Deprivation Therapy and Cataract Incidence Among Elderly Prostate Cancer Patients in the United States

Annals of Epidemiology

Volumn 21, Issue 3, 2011, Pages 156-163

  Beebe Dimmer, Jennifer ^a,b   Morgenstern, Hal ^d   Cetin, Karynsa ^f   Yee, Cecilia ^a,b   Bartoces, Monina ^c   Shahinian, Vahakn ^e   Fryzek, Jon ^f   Acquavella, John ^f   Schwartz, Kendra L ^a,c  

^a KARMANOS CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f AMGEN INC   (United States)

Author keywords

Epidemiology; GnRH Agonist; Lens Opacities; Orchiectomy; Prostate Cancer; SEER Medicare

Indexed keywords

GONADORELIN AGONIST;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER SURGERY; CATARACT; CONTROLLED STUDY; DATA BASE; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORBIDITY; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; UNITED STATES;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CATARACT; HUMANS; INCIDENCE; MALE; ORCHIECTOMY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 79551506145     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annepidem.2010.10.003     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Lu-Yao G.L., Albertsen P.C., Moore D.F., Shih W., Lin Y., DiPaola R., et al. Outcomes of localized prostate cancer following conservative management. JAMA 2009, 302:1202-1209.
3. Etzioni R., Gulati R., Falcon S., Penson D.F. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: A surveillance modeling approach. Med Decis Making 2008, 28:323-331.
4. Guise T.A., Oefelein M.G., Eastham J.A., Cookson M.S., Higano C.S., Smith M.R. Estrogenic side effects of androgen deprivation therapy. Rev Urol 2007, 9:163-180.
5. Congdon N., Vingerling J.R., Klein B.E., West S., Friedman D., Kempen J., et al. Prevalence of cataract and pseudophakia/aphakia among adults in the United States. Arch Ophthalmol 2004, 122:487-494.
6. Ellwein L.B., Urato C.J. Use of eye care and associated charges among the Medicare population: 1991-1998. Arch Ophthalmol 2002, 120:804-811.
7. Abraham A.G., Condon N.G., West G.E. The new epidemiology of cataract. Ophthalmol Clin North Am 2006, 19:415-425.
8. West S. Epidemiology of cataract: Accomplishments over 25 years and future directions. Ophthalmic Epidemiol 2007, 14:173-178.
9. Curtis J.R., Westfall A.O., Allison J., Bijlsma J., Freeman A., George V., et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006, 55:420-426.
10. Hiller R., Sperduto R.D., Ederer F. Epidemiologic associations with nuclear, cortical, and posterior subcapsular cataracts. Am J Epidemiol 1986, 124:916-925.
11. Jacques P.F., Moeller S.M., Hankinson S.E., Chylack L., Rogers G., Tung W., et al. Weight status, abdominal adiposity, diabetes, and early age-related lens opacities. Am J Clin Nutr 2003, 78:400-405.
12. Weintraub J.M., Willett W.C., Rosner B., Colditz G.A., Seddon J.M., Hankinson S.E. A prospective study of the relationship between body mass index and cataract extraction among US women and men. Int J Obes Relat Metab Disord 2002, 26:1588-1595.
13. Michaelson M.D., Cotter S.E., Gargollo P.C., Zietman A.L., Dahl D.M., Smith M.R. Management of complications of prostate cancer treatment. CA Cancer J Clin 2008, 58:196-213.
14. Potosky A.L., Riley G.F., Lubitz J.D., Mentnech R.M., Kessler L.G. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993, 31:732-748.
15. Available at: 2010. Accessed October 26, 2010. http://healthservices.cancer.gov/seermedicare/considerations/prostate.html.
16. Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164.
17. Bach P.B., Guadagnoli E., Schrag D., Schussler N., Warren J.L. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med. Care 2002, 40. IV-25.
18. Cefle K., Ozturk S., Gozum N., Duman N., Mantar F., Guler K., Palanduz S., et al. Lens opacities in Bloom syndrome: Case report and review of the literature. Ophthalmic Genet 2007, 28:175-178.
19. Ehara H., Utsunomiya Y., Ieshima A., Maegaki Y., Nishimura G., Takeshita K., Ohno K. Martsolf syndrome in Japanese siblings. Am J Med Genet A 2007, 143A:973-978.
20. Smith M.R., Finkelstein J.S., McGovern F.J., Zietman A., Fallon M., Schoenfeld D., Kantoff P. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87:599-603.
21. Smith M.R. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology 2004, 63:742-745.
22. Smith M.R. Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev 2002, 21:159-166.
23. Smith M.R. Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Curr Urol Rep 2008, 9:197-202.
24. Smith M.R. Changes in body composition during hormonal therapy for prostate cancer. Clin Prostate Cancer 2003, 2:18-21.
25. Keating N.L., O'Malley A.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24:4448-4456.
26. Al-Enezi A., Kehinde E.O., Behbehani A.M., Sheikh Z.A. Luteinizing hormone-releasing hormone analogue-induced cataract in a patient with prostate cancer. Med Princ Pract 2007, 16:161-163.
27. Salas M., Hofman A., Stricker B.H. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999, 149:981-983.
28. Messing E. The timing of hormone therapy for men with asymptomatic advanced prostate cancer. Urol Oncol 2003, 21:245-254.
29. Chodak G.W., Keane T., Klotz L. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 2002, 60:201-208.
30. Warren J.L., Klabunde C.N., Schrag D., Bach P.B., Riley G.F. Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 2002, 40. IV-18.